Lilac Petal Results Lie in the Interpretation of the DataOn March 25, 2009, Neurocrine Biosciences, Inc. (NBIX) reported results from the phase II -702 study, also called Lilac Petal, testing elagolix for the treatment of endometriosis.Elagolix met the primary efficacy goal for both the 150mg and 250mg on the clinically validated PGI-C scale for both overall lower PGI-C score and percent of women with a score below 2. The 150mg dose was also statistically significant for the clinically validated EHP scale.Management was also able to show a statistically significant reduction in baseline for the NRS-peak scale and dysmenorrhea (DYS).  The trial failed to show a significant reduction in NMPP or the NRS-mean scale, both which management hypothesized where measuring the same thing -- non-menstrual pelvic pain on a daily basis -- to a correlation of 0.9, and both which started with baseline ...